(PCVX) Vaxcyte - Overview
Exchange: NASDAQ •
Country: United States •
Currency: USD •
Type: Common Stock •
ISIN: US92243G1085
Stock: Vaccines, Pneumococcal, Bacterial, Protein
Total Rating 26
Risk 70
Buy Signal -0.28
| Risk 5d forecast | |
|---|---|
| Volatility | 47.8% |
| Relative Tail Risk | -8.33% |
| Reward TTM | |
|---|---|
| Sharpe Ratio | 0.17 |
| Alpha | -43.86 |
| Character TTM | |
|---|---|
| Beta | 1.582 |
| Beta Downside | 3.360 |
| Drawdowns 3y | |
|---|---|
| Max DD | 76.22% |
| CAGR/Max DD | 0.18 |
Description: PCVX Vaxcyte March 05, 2026
Vaxcyte, Inc. (PCVX) is a clinical-stage biotechnology company focused on developing vaccines for bacterial infectious diseases. The companys business model centers on advancing a pipeline of conjugate and novel protein vaccines.
Its primary vaccine candidate, VAX-24, is a 24-valent pneumococcal conjugate vaccine (PCV) targeting invasive pneumococcal disease (IPD) in infants. Vaxcyte also has VAX-31, a 31-valent PCV for adults and children, and several other vaccine candidates in development, including for Group A Streptococcus and periodontitis. The biotechnology sector is characterized by high research and development costs and a long development timeline for new products.
The company, incorporated in 2013 and headquartered in San Carlos, California, changed its name from SutroVax, Inc. in 2020. Understanding a companys pipeline and clinical trial stages is crucial; further research on platforms like ValueRay can provide detailed insights into these aspects.
Piotroski VR‑10 (Strict, 0-10) 0.0
| Net Income: error (cannot be calculated; needs Net Income TTM and Revenue TTM) |
| FCF/TA: -0.22 > 0.02 and ΔFCF/TA -5.51 > 1.0 |
| NWC/Revenue: error (cannot be calculated; needs Current Assets/Liabilities and Revenue current+prev) |
| CFO/TA -0.22 > 3% & CFO -655.6m > Net Income -766.6m |
| Net Debt/EBITDA: error (EBITDA <= 0) |
| Current Ratio: 7.91 > 1.5 & < 3 |
| Outstanding Shares: last quarter (136.1m) vs 12m ago 10.78% < -2% |
| Gross Margin: error (current vs previous; cannot be calculated due to missing/invalid data or negative margin) |
| Asset Turnover: 0.0% > 50% (prev 0.0%; Δ 0.0% > 0%) |
| Interest Coverage Ratio: -20.13 > 6 (EBITDA TTM -781.8m / Interest Expense TTM -40.1m) |
Altman Z'' -7.17
| A: 0.47 (Total Current Assets 1.63b - Total Current Liabilities 205.8m) / Total Assets 3.05b |
| B: -0.71 (Retained Earnings -2.15b / Total Assets 3.05b) |
| C: -0.25 (EBIT TTM -806.7m / Avg Total Assets 3.28b) |
| D: -5.97 (Book Value of Equity -2.15b / Total Liabilities 360.5m) |
| Altman-Z'' Score: -7.17 = D |
Beneish M
| DSRI: none (Receivables 46.6m/20.7m, Revenue 0.0/0.0) |
| GMI: 1.00 (fallback, negative margins) |
| AQI: 0.77 (AQ_t 0.30 / AQ_t-1 0.40) |
| SGI: none (Revenue 0.0 / 0.0) |
| TATA: -0.04 (NI -766.6m - CFO -655.6m) / TA 3.05b) |
| Beneish M-Score: cannot calculate (missing components) |
What is the price of PCVX shares?
As of March 05, 2026, the stock is trading at USD 60.13 with a total of 1,359,702 shares traded.
Over the past week, the price has changed by -4.62%, over one month by +8.77%, over three months by +30.52% and over the past year by -14.39%.
Over the past week, the price has changed by -4.62%, over one month by +8.77%, over three months by +30.52% and over the past year by -14.39%.
Is PCVX a buy, sell or hold?
Vaxcyte has received a consensus analysts rating of 4.90.
Therefore, it is recommended to buy PCVX.
- StrongBuy: 9
- Buy: 1
- Hold: 0
- Sell: 0
- StrongSell: 0
What are the forecasts/targets for the PCVX price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | 109 | 81.3% |
| Analysts Target Price | 109 | 81.3% |
PCVX Fundamental Data Overview March 01, 2026
P/B = 2.9774
Revenue TTM = 0.0 USD
EBIT TTM = -806.7m USD
EBITDA TTM = -781.8m USD
Long Term Debt = 222.7m USD (estimated: total debt 228.8m - short term 6.12m)
Short Term Debt = 6.12m USD (from shortTermDebt, last quarter)
Debt = 228.8m USD (from shortLongTermDebtTotal, last quarter)
Net Debt = 54.9m USD (from netDebt column, last quarter)
Enterprise Value = 7.63b USD (8.97b + Debt 228.8m - CCE 1.56b)
Interest Coverage Ratio = -20.13 (Ebit TTM -806.7m / Interest Expense TTM -40.1m)
EV/FCF = -11.40x (Enterprise Value 7.63b / FCF TTM -669.3m)
FCF Yield = -8.77% (FCF TTM -669.3m / Enterprise Value 7.63b)
FCF Margin = unknown (Revenue TTM is 0 or missing)
Net Margin = unknown
Gross Margin = unknown ((Revenue TTM 0.0 - Cost of Revenue TTM 0.0) / Revenue TTM)
Tobins Q-Ratio = 2.51 (Enterprise Value 7.63b / Total Assets 3.05b)
Interest Expense / Debt = 4.69% (Interest Expense 10.7m / Debt 228.8m)
Taxrate = 21.0% (US default 21%)
NOPAT = -637.3m (EBIT -806.7m * (1 - 21.00%)) [loss with tax shield]
Current Ratio = 7.91 (Total Current Assets 1.63b / Total Current Liabilities 205.8m)
Debt / Equity = 0.09 (Debt 228.8m / totalStockholderEquity, last quarter 2.69b)
Debt / EBITDA = -0.07 (negative EBITDA) (Net Debt 54.9m / EBITDA -781.8m)
Debt / FCF = -0.08 (negative FCF - burning cash) (Net Debt 54.9m / FCF TTM -669.3m)
Total Stockholder Equity = 2.96b (last 4 quarters mean from totalStockholderEquity)
RoA = -23.38% (Net Income -766.6m / Total Assets 3.05b)
RoE = -25.88% (Net Income TTM -766.6m / Total Stockholder Equity 2.96b)
RoCE = -25.33% (EBIT -806.7m / Capital Employed (Equity 2.96b + L.T.Debt 222.7m))
RoIC = -20.86% (negative operating profit) (NOPAT -637.3m / Invested Capital 3.05b)
WACC = 11.54% (E(8.97b)/V(9.19b) * Re(11.74%) + D(228.8m)/V(9.19b) * Rd(4.69%) * (1-Tc(0.21)))
Discount Rate = 11.74% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: 100.0 | Cagr: 14.16%
[DCF] Fair Price = unknown (Cash Flow -669.3m)
EPS Correlation: -64.67 | EPS CAGR: -46.64% | SUE: -0.97 | # QB: 0
Revenue Correlation: -0.00 | Revenue CAGR: 0.0% | SUE: 0.0 | # QB: 0
EPS next Quarter (2026-06-30): EPS=-1.85 | Chg7d=-0.253 | Chg30d=-0.253 | Revisions Net=+0 | Analysts=5
EPS current Year (2026-12-31): EPS=-7.39 | Chg7d=-1.210 | Chg30d=-1.172 | Revisions Net=-2 | Growth EPS=-31.3% | Growth Revenue=+0.0%
EPS next Year (2027-12-31): EPS=-7.29 | Chg7d=-0.140 | Chg30d=-0.146 | Revisions Net=-2 | Growth EPS=+1.4% | Growth Revenue=+0.0%
[Analyst] Revisions Ratio: -1.00 (0 Up / 2 Down within 30d for Current Year)
Revenue TTM = 0.0 USD
EBIT TTM = -806.7m USD
EBITDA TTM = -781.8m USD
Long Term Debt = 222.7m USD (estimated: total debt 228.8m - short term 6.12m)
Short Term Debt = 6.12m USD (from shortTermDebt, last quarter)
Debt = 228.8m USD (from shortLongTermDebtTotal, last quarter)
Net Debt = 54.9m USD (from netDebt column, last quarter)
Enterprise Value = 7.63b USD (8.97b + Debt 228.8m - CCE 1.56b)
Interest Coverage Ratio = -20.13 (Ebit TTM -806.7m / Interest Expense TTM -40.1m)
EV/FCF = -11.40x (Enterprise Value 7.63b / FCF TTM -669.3m)
FCF Yield = -8.77% (FCF TTM -669.3m / Enterprise Value 7.63b)
FCF Margin = unknown (Revenue TTM is 0 or missing)
Net Margin = unknown
Gross Margin = unknown ((Revenue TTM 0.0 - Cost of Revenue TTM 0.0) / Revenue TTM)
Tobins Q-Ratio = 2.51 (Enterprise Value 7.63b / Total Assets 3.05b)
Interest Expense / Debt = 4.69% (Interest Expense 10.7m / Debt 228.8m)
Taxrate = 21.0% (US default 21%)
NOPAT = -637.3m (EBIT -806.7m * (1 - 21.00%)) [loss with tax shield]
Current Ratio = 7.91 (Total Current Assets 1.63b / Total Current Liabilities 205.8m)
Debt / Equity = 0.09 (Debt 228.8m / totalStockholderEquity, last quarter 2.69b)
Debt / EBITDA = -0.07 (negative EBITDA) (Net Debt 54.9m / EBITDA -781.8m)
Debt / FCF = -0.08 (negative FCF - burning cash) (Net Debt 54.9m / FCF TTM -669.3m)
Total Stockholder Equity = 2.96b (last 4 quarters mean from totalStockholderEquity)
RoA = -23.38% (Net Income -766.6m / Total Assets 3.05b)
RoE = -25.88% (Net Income TTM -766.6m / Total Stockholder Equity 2.96b)
RoCE = -25.33% (EBIT -806.7m / Capital Employed (Equity 2.96b + L.T.Debt 222.7m))
RoIC = -20.86% (negative operating profit) (NOPAT -637.3m / Invested Capital 3.05b)
WACC = 11.54% (E(8.97b)/V(9.19b) * Re(11.74%) + D(228.8m)/V(9.19b) * Rd(4.69%) * (1-Tc(0.21)))
Discount Rate = 11.74% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: 100.0 | Cagr: 14.16%
[DCF] Fair Price = unknown (Cash Flow -669.3m)
EPS Correlation: -64.67 | EPS CAGR: -46.64% | SUE: -0.97 | # QB: 0
Revenue Correlation: -0.00 | Revenue CAGR: 0.0% | SUE: 0.0 | # QB: 0
EPS next Quarter (2026-06-30): EPS=-1.85 | Chg7d=-0.253 | Chg30d=-0.253 | Revisions Net=+0 | Analysts=5
EPS current Year (2026-12-31): EPS=-7.39 | Chg7d=-1.210 | Chg30d=-1.172 | Revisions Net=-2 | Growth EPS=-31.3% | Growth Revenue=+0.0%
EPS next Year (2027-12-31): EPS=-7.29 | Chg7d=-0.140 | Chg30d=-0.146 | Revisions Net=-2 | Growth EPS=+1.4% | Growth Revenue=+0.0%
[Analyst] Revisions Ratio: -1.00 (0 Up / 2 Down within 30d for Current Year)